iGlarLixi在2型糖尿病中长达52周的持久疗效:LixiLan-G扩展研究
LixiLan-G试验中,经GLP-1 RA治疗未控制的2型糖尿病患者换用iGlarLixi(甘精胰岛素100 U/mL与利司那肽固定比例复方制剂)26周后血糖控制改善。预设的26周单臂扩展研究显示,iGlarLixi的疗效和安全性在52周内得以维持。
要点
- 换用iGlarLixi后26周HbA1c均值6.7%,52周仍为6.7%,疗效持久。
- 52周时HbA1c<7%达标率64%,与26周62%相似。
- 无症状性低血糖且达标比例26周57%、52周58%,安全性稳定。
核心结论
- iGlarLixi在26周随机治疗期结束时显示的疗效和安全性在随后26周扩展期内得以维持。
研究设计与样本
- LixiLan-G试验预设的26周单臂扩展研究,纳入经GLP-1 RA治疗未控制(HbA1c 7-9% [53-75 mmol/mol])的2型糖尿病患者,完成26周主要终点且随机至iGlarLixi者继续开放标签治疗26周。
主要发现
- iGlarLixi治疗26周时平均HbA1c为6.7% [50 mmol/mol],52周时仍为6.7% [50 mmol/mol]。
- 52周时相对基线平均变化为-1.0 ± 0.9% [11 ± 10 mmol/mol]。
- HbA1c<7% (53 mmol/mol)达标率26周为62%,52周为64%。
- 达标且无 documented symptomatic (<3.0 mmol/L) 低血糖的比例26周为57%,52周为58%。
- 26周与52周安全性相似,documented symptomatic低血糖和胃肠道事件发生率均低。
临床怎么用
- 对于GLP-1 RA治疗未控制的2型糖尿病患者,换用iGlarLixi可考虑作为改善血糖控制并维持长期疗效的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes uncontrolled with GLP-1 RAs over 26 weeks versus continuing prior GLP-1 RA. A prespecified, 26-week, single-arm extension of LixiLan-G aimed to determine the durability of iGlarLixi efficacy and safety over 52 weeks. RESEARCH DESIGN AND METHODS: Participants with type 2 diabetes uncontrolled by GLP-1 RAs (glycated hemoglobin [HbA1c] 7-9% [53-75 mmol/mol]) were initially randomized to switch to iGlarLixi or continue prior GLP-1 RA. Those randomized to iGlarLixi who completed the 26-week primary end point period could continue iGlarLixi open-label treatment over a 26-week extension to assess durability of efficacy and safety. RESULTS: Glycemic control achieved with iGlarLixi at week 26 (mean HbA1c 6.7% [50 mmol/mol]) was maintained at week 52 (mean HbA1c 6.7% [50 mmol/mol]; mean ± SD change from baseline at week 52: -1.0 ± 0.9% [11 ± 10 mmol/mol]). Proportions of participants reaching HbA1c <7% (53 mmol/mol) with iGlarLixi were similar at week 26 (62%) and 52 (64%), as were those reaching this target without documented symptomatic (<3.0 mmol/L) hypoglycemia (57% and 58%). Safety of iGlarLixi was similar at weeks 26 and 52, with low rates of documented symptomatic hypoglycemia and gastrointestinal events. CONCLUSIONS: The efficacy and safety of iGlarLixi at the end of the 26-week randomized treatment period was maintained over the 26-week extension period in the LixiLan-G trial.
引用
- Blonde L, Rosenstock J, Frias J, et al. Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes Care. 2021. PMID: 33468520. doi:10.2337/dc20-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。